Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Faldaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 1.00 |
| ▸ | PPP3CB | P16298 | 1/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.55 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Faldaprevir SCHEMBL7736941 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL19246297 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL15462595 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL25524320 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL13556415 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL24058604 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL227410 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL31554839 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL7736946 | 0.96 | CTSB (0.93) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL11947501 | 0.96 | CTSB (0.93) | CTSBPPP3CBABCC1ABCC2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| EP-3993809-B1 | SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766 | EISAI R&D MAN CO LTD (JP) | 2024-10-09 | — | — | EP | claimed |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2024-10-03 | — | — | US | claimed |
| EP-4370128-A1 | TREATMENT OF INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2024-05-22 | — | — | EP | claimed |
| CN-117586329-A | Crystalline forms of hepatitis c inhibitors and their use in medicine | 广东东阳光药业股份有限公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2024032718-A1 | CRYSTAL FORM OF HEPATITIS C INHIBITOR AND USE THEREOF IN DRUG | 广东东阳光药业股份有限公司 | 2024-02-15 | — | — | WO | claimed |
| WO-2024017234-A1 | SALT OF HCV INHIBITOR, CRYSTAL FORM OF SALT, PHARMACEUTICAL COMPOSITION OF SALT, AND USE OF SALT | 广东东阳光药业股份有限公司 | 2024-01-25 | — | — | WO | claimed |
| CN-117417327-A | Salt of HCV inhibitor, crystalline form of salt, pharmaceutical composition thereof and use thereof | 广东东阳光药业股份有限公司 | 2024-01-19 | — | — | CN | claimed |
| US-20230372370-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF COVID-19 | Orcosa Inc. (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023161326-A1 | COMPOUND FOR USE IN AND METHODS OF TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-08-31 | — | — | WO | claimed |
| WO-2023285405-A1 | TREATMENT OF INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2023-01-19 | — | — | WO | claimed |
| US-20220304982-A1 | SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-09-29 | — | — | US | claimed |
| EP-3993809-A1 | SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766 | Eisai R&D Management Co., Ltd. (JP) | 2022-05-11 | — | — | EP | claimed |
| US-20220099672-A1 | Method for Treating and/or Preventing Bacteriophage Lysis During Fermentation | LOCUS SOLUTIONS, LLC | 2022-03-31 | — | — | US | claimed |
| EP-3963087-A1 | IDENTIFICATION AND ANALYSIS OF MICROBIAL SAMPLES BY RAPID INCUBATION AND NUCLEIC ACID ENRICHMENT | Illumina Inc (US) | 2022-03-09 | — | — | EP | claimed |
| EP-4747381-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PD-L1 | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20110177030-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-21 | — | — | US | disclosed |
| US-7939667-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | CTSB 214/4885PPP3CB 29/4885ABCC1 646/4885 |
| US-20240325404-A1 | TREATMENT OF INFLAMMATORY DISEASES | IFNAR1, IFNG, IRF3 | CTSB 369/4885PPP3CB 1259/4885ABCC1 378/4885 |
| US-20220304982-A1 | SYSTEM FOR ENHANCING THERAPEUTIC COMPLIANCE OF THE ANTI-CANCER COMPOUND E7766 | UGT1A6, ABCC1, CUL1 | CTSB 3593/4885PPP3CB 3000/4885ABCC1 2/4885 |
| US-20110177030-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | CTSB 103/4885PPP3CB 722/4885ABCC1 121/4885 |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | BDKRB2, BDKRB1, HRH2 | CTSB 722/4885PPP3CB 4767/4885ABCC1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.